Abstract
On the other hand, a possible mutation in CHAT which is first responsible gene for presynaptic CMS has been proposed to be scrutinized according to the literature. CHAT encodes the enzyme choline acetyltransferase and its deficiency is known for causing CMS with apnoeic episodes (EA) (5).
The objectives of our study tackled the screening for founder mutations involving in CHRNE, CHAT, and RAPSN. It has also compared the frequency of founder mutation p. Asn88Lys in RAPSN in different populations.
Materials & Methods
The study cases consisted of 16 In neurological examination, the patients had motor delay, Ptosis and muscle weakness that was worst with activity and lack of sleep. Deep tendon reflexes were diminished and plantar reflexes were downward.
We evaluated all patients with electromyography examination and the result showed more than 10% decrement that confirmed the diagnosis of Myasthenia.
Furthermore, antibodies against the Ach choline receptors were negative; therefore, they are not the cases of Myasthenia gravis. 82% of our patients were offspring of consanguineous marriage and the sign and symptoms were started in early weeks and months of life. On the other hand, the other diagnoses about motor delay and lower motor neuron diseases such as mitochondrial disorders, and congenital myopathy hypothyroidism were ruled out.
In genetic study, blood samples were obtained from the patients and genomic DNA was isolated using blood DNA extraction kit (MBST, Tehran, Iran). Target mutation analysis for previously reported mutations in 11 and 12 of CHRNE, exon 5 of CHAT and, exon 2 of RAPSN gene was performed with primers in Table 1 . In addition, Primer sequence for exon 2 of RAPSN gene was ordered (6) .
The PCR reactions were performed in a thermal cycler (Techne, Genius, UK) for 5 min at 95 °C followed by 35 cycles of denaturation for 1 min at 94 °C, annealing for 1 min depending on melting temperature of primers ( The CHRNE mutation c.1327delG were found in up to 50% of individuals of European Roma (7, 10) . Whereas the RAPSN c.264C>A mutation due to a founder effect accounting for about 90% of patients' origination from Europe (11) . Table 3 In conclusion, the outcome of this study has extended the genotype spectrum of Iranian with CMS, conferring a way to a more effective method for career detection, genetic diagnosis and counseling of Iranian patients with CMS disorders.
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